Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
199.50
-1.01 (-0.50%)
Official Closing Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
Beat the Nasdaq With This Cash-Gushing Dividend Stock
October 23, 2024
The company is performing well despite recently losing its biggest growth driver.
Via
The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
October 23, 2024
These three Vanguard ETFs are worth considering for the long term.
Via
The Motley Fool
Topics
ETFs
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
October 22, 2024
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.
Via
Talk Markets
3 Growth Stocks That Could Be Bargain Buys Right Now
October 18, 2024
These stocks trade at less than 20 times their estimated future profits.
Via
The Motley Fool
Market Analysis: AbbVie And Competitors In Biotechnology Industry
October 17, 2024
Via
Benzinga
Looking Into AbbVie's Recent Short Interest
October 14, 2024
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
October 10, 2024
Via
Benzinga
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
October 17, 2024
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, offering improved motor control and reduced symptoms. Approval was based on a...
Via
Benzinga
Exposures
Product Safety
AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories
October 17, 2024
AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says.
Via
Benzinga
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
October 14, 2024
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb.
Via
Benzinga
2 Magnificent Dividend Stocks to Buy and Hold Forever
October 14, 2024
These companies have compelling track records.
Via
The Motley Fool
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
October 14, 2024
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.
Via
MarketBeat
AbbVie's Options: A Look at What the Big Money is Thinking
October 09, 2024
Via
Benzinga
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
October 07, 2024
Via
Benzinga
Comparing AbbVie With Industry Competitors In Biotechnology Industry
October 03, 2024
Via
Benzinga
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
October 14, 2024
Buying these stocks gives you a great chance to beat the benchmark.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
October 12, 2024
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock.
Via
Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
October 12, 2024
This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
October 11, 2024
AbbVie is tracking for a new high that may be reached before the end of the year. Acquisitions fuel the growth outlook, cash flow and capital returns.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
October 08, 2024
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set...
Via
Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
October 03, 2024
Via
Benzinga
Biotech Stocks Poised For Another Big Move In Q4
October 07, 2024
The healthcare sector can be a safe haven if volatility increases.
Via
Talk Markets
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
October 06, 2024
Declining earnings haven't scared billionaire investors away from this stock.
Via
The Motley Fool
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
October 05, 2024
These companies can lend growth and dividend returns to a long-term investor's portfolio.
Via
The Motley Fool
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
October 04, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
3 Industries Set To Explode When Interest Rates Drop
October 03, 2024
Via
Talk Markets
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
October 03, 2024
Blue Shield of California partners with Fresenius Kabi and Evio Pharmacy to cut the cost of Humira's biosimilar to $525 per month, with most members paying $0 out of pocket starting January 2025.
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
70
71
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.